Price
Financials
Standalone, Rs crore| Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.04 | 0.02 | 0.01 | 0.11 | 0.04 | 0.01 | 0.01 | 0.04 | 0.01 | 0.01 | 0.01 | 0.12 |
| Operating Profit | -0.04 | -0.02 | -0.01 | -0.11 | -0.04 | -0.01 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.12 |
| OPM % | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.07 | -0.05 | -0.04 | -0.14 | -0.05 | -0.01 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.07 | -0.05 | -0.04 | -0.14 | -0.04 | -0.01 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.12 |
| EPS in Rs | -0.14 | -0.10 | -0.08 | -0.27 | -0.08 | -0.02 | -0.02 | -0.08 | -0.02 | -0.02 | -0.02 | -0.23 |
| Mar 2006 | Mar 2007 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.12 | 3.03 | 0.05 | 0.05 | 0.08 | 0.41 | 0.17 | 0.20 | 0.11 | 0.08 | 0.15 |
| Operating Profit | -0.12 | -3.03 | -0.05 | -0.05 | -0.08 | -0.41 | -0.17 | -0.20 | -0.11 | -0.08 | -0.15 |
| OPM % | |||||||||||
| Other Income | 0.00 | 5.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.48 | 0.00 | 0.00 | 0.00 |
| Interest | 2.63 | 3.34 | 2.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.02 | 0.00 |
| Profit before tax | -2.75 | -0.56 | -2.82 | -0.05 | -0.08 | -0.41 | -0.17 | -1.72 | -0.14 | -0.10 | -0.15 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -2.75 | -0.56 | -2.82 | -0.05 | -0.08 | -0.41 | -0.17 | -1.73 | -0.14 | -0.10 | -0.15 |
| EPS in Rs | -5.33 | -1.09 | -5.47 | -0.10 | -0.16 | -0.79 | -0.33 | -3.35 | -0.27 | -0.19 | -0.29 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | % | ||
| Compounded Profit Growth | 7% | -6% | 12% | -50% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | % | % | % |
| Mar 2006 | Mar 2007 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.16 | 5.16 | 5.16 | 5.16 | 5.16 | 5.16 |
| Reserves | -18.39 | -18.95 | -24.39 | -24.43 | -20.72 | -21.12 | -21.29 | -23.51 | -10.74 | -10.85 |
| Borrowings | 19.07 | 19.53 | 24.96 | 25.00 | 21.28 | 21.29 | 21.46 | 21.62 | 8.81 | 8.89 |
| Other Liabilities | 0.72 | 0.72 | 0.72 | 0.72 | 0.73 | 0.01 | 0.01 | 0.03 | 0.03 | 0.05 |
| Total Liabilities | 6.49 | 6.39 | 6.38 | 6.38 | 6.45 | 5.34 | 5.34 | 3.30 | 3.26 | 3.25 |
| Fixed Assets | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 | 0.32 | 0.28 | 0.26 |
| CWIP | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.01 | 0.01 | 0.01 |
| Investments | 2.95 | 2.95 | 2.95 | 2.95 | 2.95 | 2.95 | 2.95 | 2.95 | 2.95 | 2.95 |
| Other Assets | 1.89 | 1.79 | 1.78 | 1.78 | 1.85 | 0.74 | 0.74 | 0.02 | 0.02 | 0.03 |
| Total Assets | 6.49 | 6.39 | 6.38 | 6.38 | 6.45 | 5.34 | 5.34 | 3.30 | 3.26 | 3.25 |
| Mar 2006 | Mar 2007 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.07 | -0.50 | -0.06 | -0.05 | -0.09 | -0.05 | -0.17 | -0.16 | -0.10 | -0.08 |
| Cash from Investing Activity | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activity | 0.07 | 0.50 | 0.06 | 0.05 | 0.00 | 0.01 | 0.16 | 0.16 | 0.10 | 0.08 |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | -0.04 | -0.01 | -0.01 | 0.00 | 0.00 |
| Free Cash Flow | -0.07 | -0.50 | -0.06 | -0.05 | -0.09 | -0.05 | -0.17 | -0.16 | -0.10 | -0.08 |
| CFO/OP | 58% | 16% | 120% | 100% | 112% | 12% | 100% | 80% | 91% | 100% |
| Mar 2006 | Mar 2007 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||
| Inventory Days | ||||||||||
| Days Payable | ||||||||||
| Cash Conversion Cycle | ||||||||||
| Working Capital Days | ||||||||||
| ROCE % | -2.10% | -0.88% | -1.41% | -7.42% | -3.19% | -5.58% | -4.31% | -3.11% |
| Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 25.59% | 25.59% | 25.59% | 25.59% | 25.59% | 25.59% | 25.59% | 25.59% |
| Public | 74.41% | 74.41% | 74.41% | 74.41% | 74.41% | 74.41% | 74.41% | 74.41% |
| No. of Shareholders | 15,516 | 15,516 | 15,513 | 15,514 | 15,512 | 15,512 | 15,508 | 15,506 |
Fundamentals
Market Cap₹ 4.13 Cr.
Current Price₹ 8.00
Book Value₹ -17.4
ROCE-3.11 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)%
Compounded Profit Growth (TTM)-50%
Standalone figures.
Valuation
P/B, 3-year average-0.55x
P/B, 5-year average-0.60x
Profitability
ROE1.77%
ROCE-3.11%
ROA-3.07%
ROE, 3-year average4.33%
ROCE, 3-year average-15.81%
ROA, 3-year average-15.80%
ROE, 5-year average3.33%
ROCE, 5-year average-11.61%
ROA, 5-year average-11.51%
ROIC (approx.)-4.70%
Per share
EPS (TTM)Rs -0.29
EPS (latest year)Rs -0.19
EPS (latest quarter)Rs -0.23
EPS, 3-year averageRs -1.27
EPS, 5-year averageRs -0.99
Book value per shareRs -11.03
Cash flow per shareRs -0.16
Free cash flow per shareRs -0.16
Leverage
Total debtRs 9 Cr
Cash and bankRs 0 Cr
Net debtRs 9 Cr
Debt to equity-1.56x
Owners' fund to total sources-175.08%
Debt to assets273.54%
Cash flow
Cash from Operating Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -0 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Statement figures
Operating profit (latest quarter)Rs -0 Cr
EBITDA (TTM)Rs -0 Cr
PBDT (TTM)Rs -0 Cr
Profit before tax (TTM)Rs -0 Cr
Net profit (TTM)Rs -0 Cr
Net profit (latest year)Rs -0 Cr
Net profit (latest quarter)Rs -0 Cr
Depreciation (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 5 Cr
ReservesRs -11 Cr
Shareholders' fundsRs -6 Cr
Total assetsRs 3 Cr
Net blockRs 0 Cr
Capital work in progressRs 0 Cr
InvestmentsRs 3 Cr
Other liabilitiesRs 0 Cr
Shares outstanding (crore)0.52
Ownership
Promoter holding25.59% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 3 of 6| serious | Negative equity Shareholders' equity is negative |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2018Sales ₹0 Cr.
Net loss ₹0 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of New Heaven Chemicals & Industries Ltd?
New Heaven Chemicals & Industries Ltd (524484) has a market capitalisation of Rs 4.13 Cr. at the close.
What were New Heaven Chemicals & Industries Ltd's latest quarterly results?
In the Mar 2018 quarter, New Heaven Chemicals & Industries Ltd sales was Rs 0 Cr with a net loss of Rs 0 Cr.